Building a new biomedical ecosystem: Pfizer's centers for therapeutic innovation

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 3, 2013, Pages 314-316

  Patel, A C ^a   Coyle, A J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DECISION MAKING; DRUG INDUSTRY; EDUCATION; MEDICAL RESEARCH; ORGANIZATION; PATENT; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; TRANSLATIONAL RESEARCH; ORGANIZATION AND MANAGEMENT; PROCEDURES;

ACADEMIES AND INSTITUTES; DRUG INDUSTRY; ORGANIZATIONAL INNOVATION; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84883195998     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.89     Document Type: Article

References (4)

1. Janero, D.R. Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergistic lingua franca. Expert Opin. Drug Discov. 7, 449-456 (2012).
2. National Institute of Health (NIH), RePORT. Research Project Grant Investigators: competing applicants, awardees, and funding rates. .
3. Schachter, B. Partnering with the professor. Nat. Biotechnol. 30, 944-952 (2012).
4. Kneller, R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat. Rev. Drug Discov. 9, 867-882 (2010).